Posted by Michael Wonder on 04 Jul 2024
Lisocabtagene maraleucel for the treatment of patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
4 July 2024 - NICE is unable to make a recommendation on the use of lisocabtagene maraleucel (Breyanzi) in the NHS for the treatment of adults with relapsed and refractory aggressive B-cell non-Hodgkin lymphoma because Celgene did not provide an evidence submission.
NICE will review this decision if Celgene decides to make a submission.
